General obesity, central obesity, and high triglycerides increase risk of precancerous polyps in colorectal cancer surveillance
Metabolic health matters for colon cancer risk in high-risk surveillance patients
This meta-analysis of 24 observational studies found that metabolic factors such as general obesity, central obesity, hypertension, and high…
Metabolic issues like obesity and diabetes raise the risk of precancerous polyps in people at higher risk for colon cancer. This analysis of…
Antimicrobial resistance reaches 33.3% in cirrhosis patients with bacterial infections across global settings
Antimicrobial resistance is rising in cirrhosis patients worldwide
This systematic review and meta-analysis examines bacterial infections in 35,180 adult patients with cirrhosis globally. The analysis report…
A global analysis of 35,180 patients with cirrhosis shows rising antimicrobial resistance and varying mortality risks.
Blood-based ctDNA tests show low sensitivity for advanced colorectal neoplasia in asymptomatic adults
Blood tests miss most early colon cancer signs in average-risk adults
This systematic review and meta-analysis of population-based prospective studies found that blood-based circulating tumour DNA tests have lo…
A large review of blood tests found they often miss early colon cancer signs in average-risk adults, though they work better for advanced di…
Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis
TyG Index Linked to Higher Fatty Liver Risk
This systematic review and meta-analysis of 212,618 participants from observational studies found that higher TyG index levels were associat…
A large analysis found that higher TyG index levels are tied to increased odds of non-alcoholic fatty liver disease. This simple blood test …
Microbiome and metabolite markers may enhance colorectal cancer detection and therapeutic guidance strategies
Microbiome markers may help detect colorectal cancer early
This narrative review discusses microbiome- and metabolite-based markers for colorectal cancer. The authors suggest these markers could impr…
New markers from gut bacteria and metabolites could improve how doctors find colorectal cancer sooner and guide treatment plans.
GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety
Review shows GLP-1 drugs may help fatty liver disease
This umbrella review evaluated twenty-three meta-analyses and systematic reviews regarding GLP-1 receptor agonists in patients with metaboli…
A review of many studies suggests GLP-1 receptor agonists may improve fatty liver disease, but the evidence is still early and needs stronge…
IL-1β inhibition may alleviate aortic aneurysm immunopathology, review suggests
Blocking IL-1 beta may help treat aortic aneurysm inflammation
This narrative review examines the role of IL-1β inhibition in aortic aneurysm. The authors argue that targeting IL-1β could alleviate immun…
A review suggests stopping IL-1 beta could calm the immune system damage inside aortic aneurysms, offering a new path for treatment.
Narrative review links gut microbial metabolites to colorectal cancer mechanisms
Gut microbes may help stop colorectal cancer growth through metabolites
This narrative review examines the role of gut microbial metabolites in colorectal cancer. The authors synthesize evidence suggesting these …
A review suggests gut microbial metabolites can either suppress or promote colorectal cancer by affecting cell growth and inflammation.
Narrative review links hidradenitis suppurativa to metabolic dysfunction and systemic inflammation
New review links skin disease to metabolic health in Hidradenitis suppurativa
This narrative review examines the association between hidradenitis suppurativa and metabolic syndrome. The authors argue that increasing ev…
A new review suggests Hidradenitis suppurativa is part of a broader inflammatory state tied to metabolic dysfunction, urging a multidiscipli…
FDA Approves Linzess (linaclotide) for IBS-C, CIC, and Pediatric Functional Constipation
FDA approves Linzess for irritable bowel syndrome and constipation in adults and children.
FDA approved Linzess (linaclotide) for irritable bowel syndrome with constipation in adults and pediatric patients 7 years and older, chroni…
The FDA approved Linzess (linaclotide) for irritable bowel syndrome with constipation in adults and children ages 7 and older, and for chron…
Bayesian network meta-analysis of drugs for pediatric NAFLD steatosis improvement
New analysis shows specific drugs help children with fatty liver disease improve liver health and lower body weight
This Bayesian network meta-analysis evaluated drugs in pediatric NAFLD patients confirmed by ultrasound or biopsy. The review synthesized da…
A large review of 1,582 children found that certain medicines helped reduce liver fat and improve blood markers. Energy-focused drugs were b…
Narrative review explores microbiome-targeting therapies for inflammatory bowel disease patients
New microbial therapies for inflammatory bowel disease show promise
This narrative review examines the potential of targeting the microbial-metabolic axis for patients with inflammatory bowel disease. The aut…
A review explores how targeting the microbial-metabolic axis might help patients with inflammatory bowel disease using treatments like fecal…